drugset / Trial / NCT00516139

Lamotrigine Extended-Release In Elderly Patients With Epilepsy

NCT00516139

Phase 3 Completed 122 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is being conducted to determine the safety and tolerability of lamotrigine (LTG) in elderly patients with epilepsy. This study will be carried out using an extended-release formulation of lamotrigine (LTG-XR) that will allow once-a-day dosing.

Timeline

Start
2007-08
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lamotrigine Small molecule

Indications